CohBar, Inc.

Leading Biotech Companies Converge at Mitochondria-Targeted Drug Development Summit to Advance Therapeutic Pipeline

• Industry leaders from Stealth BioTherapeutics, Cohbar, and GenSight Biologics will gather at the exclusive Mitochondria-Targeted Drug Development Digital Summit to share breakthrough research developments. • The summit will showcase innovative approaches including Mitokinin's PINK1 activation for Parkinson's disease and Larimar Therapeutics' CTI-1601 protein replacement therapy for Friedreich's Ataxia. • Over 80 key industry experts will participate in 20+ hours of content and workshops, focusing on advancing therapeutics for mitochondrial and age-related diseases.